Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2015
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Hepatic encephalopathy
- Focus Adverse reactions
- Acronyms HALT-HE
- Sponsors Hyperion Therapeutics
- 27 Jun 2014 New trial record